Today, the President & CEO of Corium, Peter Staple, exercised options of Corium (NASDAQ: CORI) for $50K.
Following this transaction Peter Staple’s holding in the company was increased by 12.9% to a total of $1.76 million. This is Staple’s first transaction since reporting a Buy transaction on DEPO back in December 2017
See today’s analyst top recommended stocks >>
Based on Corium’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $10.06 million and GAAP net loss of $18.01 million. In comparison, last year the company earned revenue of $7.35 million and had a GAAP net loss of $11.04 million. Currently, Corium has an average volume of 322.2K. The Company has a Price to Book ratio of 8.4681.
Starting in January 2016, CORI received 57 Buy ratings in a row. Seven different firms, including Merrill Lynch and Cantor Fitzgerald, currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corium International, Inc. is a commercial stage biopharmaceutical company, which develops, manufactures and commercializes pharmaceutical products. The company development platforms enable transdermal delivery of large molecules or biologics, including vaccines, peptides and proteins, as well as small molecules that are otherwise difficult to deliver in a transdermal dosage form. The firm offers its products under the brands Corplex and MicroCor. Corium International was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1999 and is headquartered in Menlo Park, CA.
